Ensign Peak Advisors
RIGL icon

Ensign Peak Advisors’s Rigel Pharmaceuticals RIGL Stock Holding History

Ensign Peak Advisors’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-85,878
Closed -$1.44M – 1719
2024
Q4 		$1.44M Buy
+85,878
New +$1.65M ﹤0.01% 1107

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's RIGL Position: Q1 2025 in Review

Ensign Peak Advisors sold out of Rigel Pharmaceuticals (RIGL) in Q1 2025, closing a stake of 85,878 shares — an estimated $1.44M sold.

Ensign Peak Advisors first reported a position in RIGL in Q4 2024 and held it in 1 quarter. The position peaked at $1.44M in Q4 2024. 123 funds tracked by Wall St. Rank hold RIGL as of Q1 2025.

  • Ensign Peak Advisors reported no remaining Rigel Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Ensign Peak Advisors sold 85,878 Rigel Pharmaceuticals shares in Q1 2025, an estimated $1.44M.
  • Ensign Peak Advisors first reported a position in Rigel Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Ensign Peak Advisors's Rigel Pharmaceuticals position peaked at $1.44M in Q4 2024.
  • 123 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2025.

Based on Ensign Peak Advisors's 13F filing for Q1 2025, filed 14 May 2025.